Synthesis, Cytotoxicity and Molecular Docking of Some Schiff Bases Derived Quinazolinone Bearing Pyrazoline | ||||
Egyptian Journal of Chemistry | ||||
Article 15, Volume 62, Special Issue (Part 1) Innovation in Chemistry, December 2019, Page 197-209 PDF (2.3 MB) | ||||
Document Type: Original Article | ||||
DOI: 10.21608/ejchem.2019.10116.1666 | ||||
View on SCiNiTO | ||||
Authors | ||||
Sahar El-Sakka 1; Mohamed Soliman2; Eman El-Sholkany2 | ||||
1Chemistry Department, Faculty of Science, Suez University | ||||
2Chemistry Department, Faculty of Science, Suez University, Suez, Egypt | ||||
Abstract | ||||
A novel quinazolinone derivatives based on 3-amino-2-[3-(4-methoxy-3-methylphenyl)-4,5-dihydro-1H-pyrazol-5-yl]-4(3H)-qunazolinones were designed, synthesized and evaluated for their in vitro cytotoxic activity against the hepatic carcinoma cell line (HepG-2), the results revealed that the tested compounds process inhibitory effects on the growth of HepG2 liver cancer cells. 3-amino-2-[3-(4-methoxy-3-methylphenyl)-4,5-dihydro-1H-pyrazol-5-yl]-4(3H)-quinazolinone showed the highest inhibition activity against HepG2 cell line (IC50 equals 67.8 µg/ml) among the tested compounds. The molecular modelling studies were performed to explore the detailed binding affinity towards the human liver carcinoma HepG2. The obtained results proved that the most active 3-amino-2-[3-(4-methoxy-3-methylphenyl)-4,5-dihydro-1H-pyrazol-5-yl]-4(3H)-quinazolinone could be useful as a template for future design, adaptation and investigation to construct more active qunazolinone analogs. Moreover, compounds were screened for antibacterial activity and none of them showed noteworthy activity. | ||||
Keywords | ||||
Quinazolinone; HePG2; Schiff base; Molecular docking; Azomethines | ||||
Statistics Article View: 612 PDF Download: 405 |
||||